Palopegteriparatide (brand name Yorvipath) is a synthetic hormone replacement therapy used for treating hypoparathyroidism in adults. It is a transiently pegylated analog of parathyroid hormone (PTH), designed as a prodrug that releases PTH(1-34) in a controlled manner to maintain calcium homeostasis. It is grouped under the following drug class(es): Hormones and Peptides. The directory classifies it as a commercial API with a peptide source/manufacturing origin. Other names for this substance include Yorvipath and ACP-014. Its PubChem SID is 505854365.
Palopegteriparatide
| CAS No | 2222514-07-8 |
|---|---|
| Molecular Formula | C₂₀₉H₃₄₀N₆₀O₅₉S₃ + 2 × (C₂H₄O)ₙ |
| Molecular Weight | ~ 48,000 Da |
| Synonyms | Poly(oxy-1,2-ethanediyl), alpha-hydro-omega-methoxy, ether with N-[[[2-[[6-[[1-[3-[[3-(2,3-dihydroxypropoxy)propyl]amino]-3-oxopropyl]-2,5-dioxo-3-pyrrolidinyl]thio]hexyl]amino]ethyl]amino]carbonyl]-2-methylalanyl-teriparatide (2:1) |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Palopegteriparatide (brand name Yorvipath) is a synthetic hormone replacement therapy used for treating hypoparathyroidism in adults. It is a transiently pegylated analog of parathyroid hormone (PTH), designed as a prodrug that releases PTH(1-34) in a controlled manner to maintain calcium homeostasis.
The listed CAS number is 2222514-07-8.
The listed molecular formula is C₂₀₉H₃₄₀N₆₀O₅₉S₃ + 2 × (C₂H₄O)ₙ.
The listed molecular weight is ~ 48,000 Da.
Poly(oxy-1,2-ethanediyl), alpha-hydro-omega-methoxy, ether with N-[[[2-[[6-[[1-[3-[[3-(2,3-dihydroxypropoxy)propyl]amino]-3-oxopropyl]-2,5-dioxo-3-pyrrolidinyl]thio]hexyl]amino]ethyl]amino]carbonyl]-2-methylalanyl-teriparatide (2:1).
The source lists Yorvipath and ACP-014.